AU2013202993B2 - Treatment of cancer with TOR kinase inhibitors - Google Patents

Treatment of cancer with TOR kinase inhibitors Download PDF

Info

Publication number
AU2013202993B2
AU2013202993B2 AU2013202993A AU2013202993A AU2013202993B2 AU 2013202993 B2 AU2013202993 B2 AU 2013202993B2 AU 2013202993 A AU2013202993 A AU 2013202993A AU 2013202993 A AU2013202993 A AU 2013202993A AU 2013202993 B2 AU2013202993 B2 AU 2013202993B2
Authority
AU
Australia
Prior art keywords
substituted
pyrazin
unsubstituted
breast cancer
dihydropyrazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013202993A
Other languages
English (en)
Other versions
AU2013202993A1 (en
Inventor
Kristen Mae Hege
Rama K. Narla
Heather Raymon
Shuichan Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of AU2013202993A1 publication Critical patent/AU2013202993A1/en
Priority to AU2015201138A priority Critical patent/AU2015201138B2/en
Application granted granted Critical
Publication of AU2013202993B2 publication Critical patent/AU2013202993B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013202993A 2012-03-15 2013-03-14 Treatment of cancer with TOR kinase inhibitors Ceased AU2013202993B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015201138A AU2015201138B2 (en) 2012-03-15 2015-03-04 Treatment of cancer with TOR kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611374P 2012-03-15 2012-03-15
US61/611,374 2012-03-15
US201261715331P 2012-10-18 2012-10-18
US61/715,331 2012-10-18
PCT/US2013/031185 WO2013138553A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015201138A Division AU2015201138B2 (en) 2012-03-15 2015-03-04 Treatment of cancer with TOR kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2013202993A1 AU2013202993A1 (en) 2013-10-03
AU2013202993B2 true AU2013202993B2 (en) 2015-09-03

Family

ID=48014333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013202993A Ceased AU2013202993B2 (en) 2012-03-15 2013-03-14 Treatment of cancer with TOR kinase inhibitors

Country Status (19)

Country Link
US (2) US20130245027A1 (https=)
EP (1) EP2825169B1 (https=)
JP (2) JP2015511963A (https=)
KR (1) KR102057359B1 (https=)
CN (1) CN104271139A (https=)
AU (1) AU2013202993B2 (https=)
BR (1) BR112014022707A2 (https=)
CA (1) CA2867348A1 (https=)
ES (1) ES2678250T3 (https=)
IL (1) IL234641B (https=)
MX (1) MX360880B (https=)
MY (1) MY178012A (https=)
NI (1) NI201400112A (https=)
NZ (1) NZ628407A (https=)
PH (1) PH12014502046B1 (https=)
SG (1) SG11201405724RA (https=)
TW (1) TWI635862B (https=)
WO (1) WO2013138553A1 (https=)
ZA (1) ZA201406701B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
CN112933088B (zh) * 2021-02-03 2022-02-22 南华大学附属第一医院 Y041-5921在制备抗肿瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2009126926A2 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2009126926A2 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERK L, et al. Cancer Chemother Pharmacol, (published online: 1 Juanuary 2012) Vol 69, pp 1369-1377. *
DEY N, et al. Eur J Can, (2011) Vol 47 Suppl 4, p S17. *
LEHMANN BD, et al. The Journal of Clinical Investigation, (2011) Vol 121, pp 2750-2767. *
LIU T, et al. Mol Cancer Ther, (2011) Vol 10, pp 1460-1469. *
MACASKILL EJ, et al. Breast Cancer Res Treat, (2011) Vol 128, pp 725-734. *
SANCHEZ CG et al. Breast Cancer Research, (2011) Vol 13, pp 1-17. *
ZENG Q, et al. European Journal of Cancer, (2010) Vol 46, pp 1132-1143. *
ZHAO H, et al. Breast Cancer Res Treat, (published online 11 March 2011), Vol 131, pp 425-436 *

Also Published As

Publication number Publication date
WO2013138553A1 (en) 2013-09-19
AU2013202993A1 (en) 2013-10-03
NI201400112A (es) 2015-01-15
TWI635862B (zh) 2018-09-21
CN104271139A (zh) 2015-01-07
EP2825169A1 (en) 2015-01-21
KR20140138951A (ko) 2014-12-04
JP2015511963A (ja) 2015-04-23
US20130245027A1 (en) 2013-09-19
IL234641A0 (en) 2014-11-30
IL234641B (en) 2020-04-30
JP2018052963A (ja) 2018-04-05
HK1201753A1 (en) 2015-09-11
NZ628407A (en) 2016-04-29
EP2825169B1 (en) 2018-05-09
ZA201406701B (en) 2016-05-25
MX2014011118A (es) 2015-04-08
MY178012A (en) 2020-09-29
BR112014022707A2 (pt) 2020-10-27
ES2678250T3 (es) 2018-08-09
CA2867348A1 (en) 2013-09-19
JP6470820B2 (ja) 2019-02-13
PH12014502046A1 (en) 2014-12-10
SG11201405724RA (en) 2014-10-30
PH12014502046B1 (en) 2020-10-16
TW201343165A (zh) 2013-11-01
MX360880B (es) 2018-11-21
KR102057359B1 (ko) 2019-12-18
US20230338370A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
AU2013203153B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2013202992B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2013203156B2 (en) Treatment of cancer with TOR kinase inhibitors
WO2013059396A2 (en) Treatment of cancer with tor kinase inhibitors
US20160008356A1 (en) Treatment of cancer with tor kinase inhibitors
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2012318272B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
AU2015200318A1 (en) Treatment of cancer with TOR kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired